Some studies suggest combining this with another serum agent—HE4 (cut-off = 70 pmol/L [18]) and preoperative inflammatory markers for differential diagnosis of ovarian cancer from benign lesions [19]. Here, WFDC2 is linked to ovarian carcinoma.